MassMutual Private Wealth & Trust’s Relmada Therapeutics RLMD Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.63K	Buy	+525	New	+$3.67K	﹤0.01%	1793
2024 Q4	–	Sell	-113	Closed	-$366	–	2352
2024 Q3	$366	Hold	113	–	–	﹤0.01%	2022
2024 Q2	$339	Hold	113	–	–	﹤0.01%	2010
2024 Q1	$525	Hold	113	–	–	﹤0.01%	1855
2023 Q4	$468	Sell	113 -57	-34%	-$169	﹤0.01%	1831
2023 Q3	$510	Sell	170 -613	-78%	-$1.82K	﹤0.01%	1820
2023 Q2	$1.93K	Buy	+783	New	+$2.17K	﹤0.01%	1478
2022 Q4	–	Sell	-92	Closed	-$3K	–	1820
2022 Q3	$3K	Buy	+92	New	+$2.55K	﹤0.01%	1128
2022 Q1	–	Sell	-28	Closed	-$1K	–	1618
2021 Q4	$1K	Buy	+28	New	+$623	﹤0.01%	1294

Other funds holding RLMD

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

MassMutual Private Wealth & Trust's RLMD Position: Q2 2026 in Review

MassMutual Private Wealth & Trust opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 525 shares worth $3.63K. The stake represents ﹤0.01% of the portfolio and ranks #1793 among its holdings. This is a return to the name: MassMutual Private Wealth & Trust previously reported a position in RLMD as recently as Q3 2024.

MassMutual Private Wealth & Trust first reported a position in RLMD in Q4 2021 and has held it in 9 quarters since. 2 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

MassMutual Private Wealth & Trust held 525 shares of Relmada Therapeutics worth $3.63K as of Q2 2026.
Relmada Therapeutics was a new MassMutual Private Wealth & Trust position in Q2 2026.
Relmada Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #1793 holding.
MassMutual Private Wealth & Trust first reported a position in Relmada Therapeutics in Q4 2021 and has held it in 9 quarters since.
2 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.